Development of Non-Traditional Therapies for Bacterial Infections; Public Workshop—August 21-22, 2018

Speakers and Panelists

Paul Ambrose, Pharm.D.
President
Institute for Clinical Pharmacodynamics, Inc.
New York, NY

Michael Bevilacqua, MD, PhD
Chief Scientific Officer/Chief Executive Officer
Amicrobe, Inc.
Carlsbad, CA

Todd Black, PhD
Director of Infectious Diseases-Drug Discovery
Merck
New York, NY

Helen Boucher, MD
Professor of Medicine,
Tufts Medical Center, Tufts University School of Medicine
Boston, MA

Edward Burd, PhD
Head of Regulatory Affairs
Rebiotix, Inc.
Roseville, MN

Cara Cassino, MD
EVP, Research and Development
Chief Medical Officer
ContraFect Corporation
Yonkers, NY

Edward Cox, MD, MPH
Director
Office of Antimicrobial Products (OAP)
OND, CDER, FDA, Silver Spring, MD

Wayne Dankner, MD
Chief Medical Officer
Atox Bio
Carrboro, North Carolina

Shampa Das, PhD
Senior Lecturer, Antimicrobial Pharmacodynamics and Therapeutics
University of Liverpool
Liverpool, UK

Mary Beth Dorr, PhD
Director, Clinical Research, Infectious Diseases
Merck
Kenilworth, NJ

Filip Dubovsky, MD
Vice President of Clinical Development, Infectious Disease
MedImmune
Gaithersburg, MD

Ann Eakin, PhD
Senior Scientific Officer, Concept Acceleration Program
Office of Biodefense, Research Resources & Translational Research/DMID/NIAID/NIH
Rockville, MD

Scott Evans, PhD
Professor of Epidemiology and Biostatistics
Director of the George Washington Biostatistics Center
George Washington University
Washington, DC

Mayurika Ghosh, MD
Medical Officer
Division of Anti-Infective Products (DAIP), OAP
OND, CDER, FDA
Silver Spring, MD

Ramya Gopinath, MD
Medical Officer
Division of Anti-Infective Products (DAIP), OAP
OND, CDER, FDA
Silver Spring, MD

William Hope, PhD
Professor of Therapeutics and Infectious Diseases
University of Liverpool
Liverpool, UK

Dmitri Iarikov, MD
Deputy Director
DAIP, OAP
OND, CDER, FDA
Silver Spring, MD

Michael Kaleko, MD, PhD
Senior Vice President, Research and Development
Synthetic Biologics, Inc.
Rockville, MD

Wes Kim, PhD
Senior Officer, Innovation; Antibiotic Resistance Project
The Pew Charitable Trusts
Washington, DC

Joe Larsen, PhD
Senior Vice President for Life Sciences
Strategic Marketing Innovations
Washington, DC

Elizabeth Leininger, PhD
Vice President of Regulatory Affairs
Aridis Pharmaceuticals
San Jose, CA

Owen McMaster, PhD
Pharmacologist
OND, CDER, FDA
Silver Spring, MD

David Melnick, MD
Chief Medical Officer
Spero Therapeutics
Cambridge, MA

Sumati Nambiar, MD, MPH
Director
DAIP, OAP
OND, CDER, FDA
Silver Spring, MD

Kevin Outterson, JD
Executive Director
CARB-X
Boston, MA

Toni Perez, MD, PhD
Chief Medical Officer
Combioxin
Geneva, Switzerland

Peter Potgieter, MD, PhD
VP, Medical Affairs
Locus Biosciences, Inc.
Research Triangle Park, NC

John Rex, MD
Chief Medical Officer & Director
F2G, Ltd
Manchester, UK

Dan Rubin, PhD
Statistician
Division of Biometrics IV, Office of Translational Sciences (OTS), CDER, FDA
Silver Spring, MD

Mary Shatzoff, MS
Senior Director of Regulatory Affairs
Target Health Inc.
New York, NY

Kalavati Suvarna, PhD
Microbiologist
DAIP, OAP
OND, CDER, FDA
Silver Spring, MD

Vu Truong, PhD
Chief Executive Officer and Director
Aridis Pharmaceuticals
San Jose, CA

Brian Tse, PhD
Health Scientist
Division of Chemical, Biological, Radiological, & Nuclear Countermeasures (CBRN)
Biomedical Advanced Research & Development Authority (BARDA)
Washington, DC

Xiaohui (Tracey) Wei, PhD
Pharmacologist
OTS, Office of Clinical Pharmacology, CDER, FDA
Silver Spring, MD

Edward Weinstein, MD
Medical Officer
DAIP, OAP
OND, CDER, FDA
Silver Spring, MD

Disclosures

Dr. Paul Ambrose is employed by and have equity in ICPD, a company that provides pharmacometric services to industry.

Dr. Todd Black is a full-time employee of Merck.

Dr. Helen Boucher has the following disclosures:

- Data Monitoring Committee: Shire
- Scientific Advisory Board: Merck
- Editor: ID Clinics of North America; Antimicrobial Agents and Chemotherapy
- Treasurer: Infectious Diseases Society of America
- Member: ID Board and ID Test Writing Committee, American Board of Internal Medicine
- Voting Member: Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB)

Dr. Burd is a full-time employee of Rebiotix.

Dr. Cara Cassino is Chief Medical Officer at ContraFect Corp and is a full-time employee of the company.

Dr. Wayne M Dankner is a full-time employee of Atox Bio.

Dr. Shampa Das holds research grants with Spero Therapeutics, Allecra, Antabio, Bugworks, NAEJA-RGM and AMR Centre. Shampa Das is also working or has previously worked as a consultant with Pfizer, TenNor, Macrolide and Italfarmaco. She is also a former employee and holder of Astrazeneca shares.

Dr. Mary Beth Dorr is a full-time employee of Merck & Co., Inc, Kenilworth, NJ.

Dr Filip Dubovsky is a full-time employee and shareholder of MedImmune/AstraZeneca.

Dr. Evans reports grants from NIAID/NIH; personal fees from the FDA, NIH, The American Statistical Association, The Society for Clinical Trials, the Clinical Trials Transformation Initiative, the American Society for Microbiology, The Infectious Disease Society for America, ACTTION, PPRECISE, the Huntington's Study Group, the Muscle Study Group, Osaka University, the National Cerebral and Cardiovascular Center of Japan, University of Rhode Island, NJMS / Rutgers, Statistical Communications in Infectious Diseases (Journal), Taylor and Francis, the City of Hope, the Austrian Breast & Colorectal Cancer Study Group (ABCSG)/Breast International Group (BIG) and the Alliance Foundation Trials (AFT) , Takeda / Millennium, Pfizer, Roche, Novartis, Achaogen, Auspex, Alcon, Merck, Chelsea, Mannkind, QRx Pharma, Genentech, Affymax, FzioMed, Amgen, GSK, Boehringer-Ingelheim, the Drug Information Association, Cubist, AstraZeneca, Teva, Repros, Zeiss, Dexcom, Claret Medical, Vir, Arrevus, Five Prime, Shire, Alexion, Gilead, Spark, Nuvelution, Syndax, Advantagene, Tracon.

Dr. William Hope holds or has recently held research grants with F2G, AiCuris, Astellas Pharma, Spero Therapeutics, Matinas Biosciences, Antabio, Amplyx, Allecra, Bugworks, NAEJA-RGM, AMR Centre, and Pfizer. He holds awards from the National Institutes of Health, Medical Research Council, National Institute of Health Research, FDA and the European Commission (FP7 and IMI). William Hope has received personal fees in his capacity as a consultant for F2G, Amplyx, Ausperix, Spero Therapeutics and BLC/TAZ. Dr. Hope is an Ordinary Council Member for the British Society of Antimicrobial Chemotherapy.

Dr. Michael Kaleko is a full-time employee of Synthetic Biologics, Inc., a public company pursuing strategies to protect the gut microbiome from antibiotic exposure.

Dr. Joe Larsen is Senior Vice President, Life Sciences at Strategic Marketing Innovations, a government relations firm. Locus Biosciences is a current client.

Dr. Leininger is currently Vice President and Head of Regulatory at Aridis Pharmaceuticals.

Dr. Melnick is a full-time employee of Spero Therapeutics, Cambridge, MA.

Professor Outterson is a professor at Boston University and the Executive Director of CARB-X. He has no financial conflicts of interest with any drug company. His research is funded by the US Government, the Wellcome Trust, the UK Government, and the Bill and Melinda Gates Foundation.

Dr. Perez is the Chief Medical Officer of Combioxin, member of GARDP (REVIVE), ESCMID Study Groups (Critically Ill Patients and Nosocomial Infections) and adviser of Abionic, Debiopharm, FP7-HEALTH-2010, Horizon 2020, EUREKA and Innovation Fund Denmark projects.

Dr. Potgieter is a full-time employee of Locus Biosciences.

Dr. John H. Rex is Chief Medical Officer & Director, F2G, Ltd.; Non-Executive Director & Consultant, Adenium Biotech ApS; Operating Partner & Consultant, Advent Life Sciences; and Expert-in-Residence, Wellcome Trust; He sits on the scientific advisory boards of Macrolide Pharmaceuticals; Bugworks Research, Inc.; Basilea Pharmaceutica; Forge Therapeutics, Inc.; and Novo Holdings; He is a shareholder in AstraZeneca Pharmaceuticals; F2G, Ltd; Adenium Biotech ApS; Advent Life Sciences; Macrolide Pharmaceuticals; and Bugworks Research, Inc.; He has received consulting fees from Phico Therapeutics; ABAC Therapeutics; Polyphor, Ltd.; Heptares Therapeutics, Ltd.; Gangagen, Ltd.; Meiji Seika Pharma; Basilea Pharmaceutica International Ltd.; Allecra Therapeutics GmbH; Forge Therapeutics, Inc.; SinSa Labs; AtoxBio; Peptilogics; F. Hoffmann-LaRoche, Ltd.; and Novo Holdings.

Mary Shatzoff is a Regulatory Affairs Executive and has been working in the pharmaceutical industry in clinical drug development for the past 20 years. She has been a Director of Regulatory Affairs at Target Health Inc. since 2006. Before she joined Target Health she worked as a Manager of Regulatory Affairs at Sanofi Aventis and a Quality Control Microbiologist at Pfizer. She is an active member of The Regulatory Affairs Professional Society (RAPS) as well as the Drug Information Association (DIA). Two of her articles have been published in Applied Clinical Trials Magazine and RAPS Focus Magazine. She received a Bachelor of Science in Biology from Northeastern University, and a Master of Science in Regulatory Affairs from Long Island University, Arnold & Marie Schwartz College of Pharmacy and Health Sciences. Certificates: Regulatory Affairs Certification (RAC-US), Certified Quality Auditor (CQA).

Dr. Vu Truong is a full-time employee of Aridis Pharmaceuticals, Inc.

Dr. Tse is a full-time employee of ASPR/BARDA. The division in which he works supports the development of new antibiotics by pharmaceutical companies, including non-traditional therapies. The pharmaceutical companies often provide cost-share in these development programs.